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Abstract
The prognosis of patients who present with non-ST segment elevation acute coronary
syndromes (ACS) is guarded. These patients can be risk-stratified on the basis of symptom
complex, electrocardiographic ST segment depression, obvious hemodynamic compromise
and particularly on the basis of serum troponin level. An elevated troponin level determines
risk and also predicts the degree of benefit from treatment with either low molecular weight
heparin or platelet glycoprotein (GP) IIb/IIIa blockade. Higher risk patients should undergo
early coronary angiography and myocardial revascularization as indicated and feasible.
Although studies performed before the advent of coronary stenting and adjunctive platelet
GP IIb/IIIa blockade suggested increased hazard for patients undergoing early intervention,
recent experience cited herein supports an in-hospital and long-term clinical benefit for the
aggressive approach. Here, I propose an algorithm for risk stratification and triage of
appropriate patients for adjunctive pharmacotherapy and early revascularization.
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Introduction
In the current era of coronary stenting and adjunctive
platelet GP IIb/IIIa blockade, efficient and effective therapy
can be offered to patients who present with non-ST
segment elevation ACS. Empirically defined durations of
medical ‘stabilization’ offer no specific advantage to this
patient population (unstable angina; non-ST elevation
acute myocardial infarction). Unfortunately, prior trials com-
paring an ‘aggressive’ (invasive) versus ‘conservative’ (non-
invasive) strategy were performed before the advent of
platelet GP IIb/IIIa blockade and coronary stenting [1,2].
These studies identified excess ‘hazard’ for early interven-
tion and appeared to confirm prior retrospective analyses
which had suggested that percutaneous coronary interven-
tion (PCI), performed at the time of diagnostic catheteriza-
tion (ad hoc) [3,4] or during the first week following
presentation for unstable angina [5], was associated with
an increased rate of procedural failure and major hospital
complications. Thus, the current Agency for Health Care
Policy and Research (AHCRP) guidelines published in
1994 promote ‘conservatism’ to avoid ‘early hazard’ and,
unfortunately, define treatment strategy (invasive versus
conservative) before adequately assessing patient risk [6].
In light of recent developments in interventional technologyCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Kereiakes
and adjunctive pharmacology as well as in our understand-
ing of accurate risk stratification, it is most appropriate at
this time to reevaluate our approach to patients with non-
ST segment elevation ACS. Let us start by defining the
magnitude and significance of this problem.
Non-ST segment elevation ACS has become the most fre-
quent admission diagnosis in the United States Medicare
population. In addition, the prognosis of this syndrome with
‘conventional’ therapy (aspirin, unfractionated heparin,
nitrates, beta blockers and no revascularization strategy)
remains guarded. Analysis of the control arms for random-
ized trials of new treatment modalities reveals an incidence
of death or nonfatal myocardial infarction of 8–15% at
30 days and 10–20% at 6 months following enrollment
[1,7–11]. Observations on the natural history of unstable
angina confirm an alarming incidence of death or myocardial
infarction (17%) and the requirement for symptom-driven
revascularization by either angioplasty (30%) or coronary
artery bypass graft surgery (CABG) in 27% of patients at
one year following presentation [12]. The ineffectiveness of
the conventional-conservative treatment strategy has been
compounded by inefficiency. Average published hospital
lengths of stay for the diagnosis of unstable angina range
from 4–14 days internationally (5 days in the USA) [13–15].
Indeed, recent data from the European ENACT registry of
unstable angina demonstrate an average intensive care unit
stay of 3.4 days with a total hospital of stay of 8.4 days [15].
These observations point to the need for more effective and
efficient treatment strategies for patients who present with
non-ST elevation ACS.
Advances in adjunctive pharmacotherapy
Randomized controlled trials have established the superi-
ority of dalteparin (versus placebo) [16] and enoxaparin
(versus unfractionated heparin) [8,17] for reducing the
occurrence of death or nonfatal myocardial infarction,
requirement for urgent revascularization or recurrence of
angina pectoris in patients who present with non-ST ele-
vation ACS [18]. The sequence of subcutaneous dal-
teparin therapy followed by random allocation to early
revascularization (average 6 days) reduced the composite
endpoint of death or nonfatal myocardial infarction to
6 months compared with subcutaneous dalteparin fol-
lowed by a conservative (no revascularization) strategy
[19]. A preliminary experience with PCI following 48 h
subcutaneous enoxaparin therapy, from the ESSENCE
trial performed in France, reported an extremely low rate of
major cardiac events and supports an ‘early invasive’ strat-
egy for this patient population [20]. Separately conducted
placebo-controlled randomized trials have proven the effi-
cacy of platelet GP IIb/IIIa blockade in reducing ischemic
events before and particularly during PCI in patients with
non-ST elevation ACS [9,10,21,22]. This benefit of
platelet GP IIb/IIIa inhibition is additive to that conferred by
aspirin and unfractionated heparin and is most evident in
those patients undergoing early PCI (< 72 h following
enrollment) [23]. In summary, adjunctive pharmacotherapy
with either low molecular weight heparin or platelet GP
IIb/IIIa blockade can improve clinical outcomes of patients
with non-ST elevation ACS, particularly when adminis-
tered in sequence with early coronary revascularization.
Revascularization strategies
Coronary stents may improve clinical outcomes in patients
with unstable angina pectoris when compared with the
results obtained with standard balloon angioplasty. In a
nonrandomized observational experience, stents (versus
balloon angioplasty) improved procedural success and
reduced death or the requirement for CABG in hospital
[24]. Nevertheless, major adverse cardiovascular events
are increased in patients with unstable angina following
coronary stent deployment [25,26]. Patients with non-ST
segment elevation ACS have abnormalities in platelet size
and function [27,28] that may be protracted following pre-
sentation [29]. This state of ‘platelet hyperactivity’ may in
part explain the previously observed hazard of early PCI
[3–5]. Conversely, adjunctive pharmacotherapy with pro-
phylactic abciximab during PCI (particularly stent deploy-
ment) significantly reduces periprocedural complications,
improves clinical outcomes and confers a long-term
(³ 1 year) survival advantage in patients with ACS
[30–32]. The survival advantage accrued by patients
treated with abciximab cannot be ascribed to stent
deployment alone [33]. In the absence of adjunctive abcix-
imab therapy, coronary stents have not been associated
with a mortality reduction [34].
‘Hazard’ of early intervention: dispelling the
myth
Recent data lead us to question the prior doctrine that
early coronary revascularization is fraught with hazard in
patients with non-ST elevation ACS. For example, the
1999 United States National Heart, Lung, and Blood Insti-
tute (NHLBI) Dynamic Registry demonstrates no increase
in major hospital complications following ‘ad hoc’ PCI
[35], despite the more frequent presence of unstable
angina and angiographically demonstrable coronary
thrombus in these patients. Coronary stents were
deployed in almost 70% and adjunctive platelet GP IIb/IIIa
blockade was administered in 36% of patients undergoing
ad hoc PCI [35]. In a separate report from the NHLBI
Dynamic Registry [36], major hospital complications
(death, Q-wave myocardial infarction or urgent bypass
surgery) were infrequently observed in patients undergo-
ing PCI for non-ST segment elevation myocardial infarc-
tion. Adjunctive platelet GP IIb/IIIa blockade was
administered in 45% of these PCI procedures. These
observations reflect improvements in interventional tech-
nology and adjunctive pharmacology. Furthermore, the
1996 New York State Cardiac Surgery database for
CABG following non-Q wave myocardial infarctionc
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demonstrates no increase in risk for mortality (adjusted
odds ratio [95% confidence interval] = 1.01 [0.51, 1.98])
when surgery is performed 3–8 days following presenta-
tion when compared with CABG for all other classes of
angina (mortality 1.3%) [37]. This experience stands in
stark contrast to the 12% in-hospital mortality reported
from the VANQWISH trial when CABG was performed
during the initial hospitalization for non-Q wave myocardial
infarction [1].
The Ohio Heart Health Center experience
In 1996, abciximab was incorporated into a practice
guideline for patients undergoing PCI by Ohio Heart
Health Center (OHHC) operators at The Christ Hospital in
Cincinnati, Ohio, USA. To assess the impact of this strat-
egy, three separate cohorts of unstable angina patients
having PCI either before (1995) or after (1997, 1998)
implementation of guideline-driven abciximab therapy were
compared [38,39]. No differences in clinical or angio-
graphic demographics were observed between cohorts.
The utilization of both abciximab and coronary stents
increased in each cohort (Fig. 1). Average preprocedural
hospital length of stay was reduced from 0.96 (1995) to
0.26 (1998) days and total hospital stay from 2.82 to 1.59
days, respectively (Fig. 2). This abbreviated hospital length
of stay was observed in 352 consecutive patients treated
in 1998 and compares favorably with the established
4–14 day length of stay for unstable angina pectoris noted
previously [13–15]. The same OHHC operators achieved
a 57% reduction in major cardiac events (death, Q-wave
myocardial infarction or urgent revascularization) in-hospi-
tal and an 81% reduction in the requirement for urgent
revascularization within 30 days following PCI (Fig. 3). The
cost increment of technology (stents and abciximab) was
more than offset by cost savings attributable to the reduc-
tions in both hospital length of stay and costly adverse
clinical outcomes (Fig. 4). Other factors contributing to the
reduced cost of care may have included a dedicated, high
volume interventional unit, capitated vendor contracts for
catheterization laboratory resources and an active clinical
research program. Similar improvement in clinical out-
comes and a net cost reduction associated with adjunc-
tive abciximab use during PCI in patients with non-ST
elevation ACS was reported by Lundstrom et al [40].
These investigators observed a reduction in the require-
ment for urgent revascularization as well as in total costs
to 6 months following PCI with adjunctive abciximab. A
recently published observational study lends further
support for an aggressive, ‘early invasive’ approach to
patients who present with non-ST elevation myocardial
infarction [41]. Patient and procedural demographics,
hospital and long-term outcomes in patients treated for
Figure 1
Percentage utilization of abciximab or coronary stents to treat unstable
angina by Ohio Heart Health Center Operators at The Christ Hospital,
Cincinnati, Ohio, USA for each treatment cohort. Adapted with
permission from [39].
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Figure 2
Preprocedure (mean ± SD) and total hospital length of stay for each
treatment cohort.
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Figure 3
Incidence of occurrence in-hospital of major adverse cardiac events
(MACE: death, Q-wave myocardial infarction [QMI], urgent coronary
revascularization) following PCI, and the requirement for urgent
revascularization (percutaneous or surgical) within 30 days by
treatment cohort. Adapted with permission from [39].
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an early invasive treatment strategy were compared with
similar data derived from hospitals favoring a noninterven-
tional or ‘early conservative’ approach. Coronary angiogra-
phy was performed in 90% of patients and early PCI
(£ 6 h) in almost half of all patients admitted to early inva-
sive hospitals [41]. Acknowledging significant differences
in baseline demographics between the patients treated at
conservative versus invasive institutions, both in-hospital
and late (4 year) survival was improved in aggressively
treated patients [41].
Appropriate patient selection
Significant improvements in the ability to risk-stratify
patients who present with non-ST elevation ACS have
evolved. The single most accurate and readily available
predictor in this population is the serum troponin level. Ele-
vation in the serum level of either troponin T or I predicts
adverse clinical outcomes [42–44]. A quantitative relation-
ship between troponin level and risk of death, myocardial
infarction or urgent revascularization has been established
[45]. Troponin is a surrogate marker for platelet-thrombus
formation, microvascular embolization and minor myocar-
dial injury. In addition to predicting risk, an elevated tro-
ponin level also predicts a beneficial response to
abciximab therapy [46]. Similar observations have been
made between elevation in serum troponin level and a
beneficial response to therapy with intravenous tirofiban or
subcutaneous dalteparin in patients with non-ST elevation
ACS [47]. Thus, troponin predicts magnitude of clinical
benefit from therapy with either platelet GP IIb/IIIa block-
ade or low molecular weight heparin. Another predictor of
risk in patients with non-ST elevation ACS is the 12-lead
electrocardiogram [2,48]. Both the presence and magni-
tude of ST segment depression on the 12-lead electrocar-
diogram correlate directly with mortality in follow-up
[2,48]. Patients who manifest signs of left ventricular
decompensation or ischemic mitral valve dysfunction
during episodes of angina should also be considered high
risk. Anginal symptoms (Braunwald classification) define
risk for subsequent adverse outcomes. Braunwald Class
III angina (rest pain < 48 h) predicts the subsequent
occurrence of death or myocardial infarction and Class c
(medically refractory angina) adversely affects survival to
30 days [49]. The correlation between Braunwald
symptom class and subsequent occurrence of ischemic
events may be explained in part by the correlation
between symptom class and the presence of thrombus on
selective coronary angiography [50,51].
Conclusion: defining appropriate care
Patients with non-ST elevation ACS should be risk-strati-
fied upon presentation. Risk can be assessed  by angina
symptom class, presence or absence of hemodynamic
compromise, electrocardiographic ST segment depres-
sion and elevation in serum troponin (Fig. 5). Patients at
high risk should undergo early angiography and revascu-
larization as indicated. Patients who have elevated serum
troponin should receive therapy with platelet GP IIb/IIIa
blockade and/or low molecular weight heparin. If PCI is
performed, coronary stent deployment is desirable and
adjunctive GP IIb/IIIa blockade is indicated unless a spe-
cific contraindication is present. Optimal long-term out-
comes, specifically a survival advantage, are conferred by
adjunctive abciximab therapy during PCI. Furthermore,
CABG performed 3–8 days following presentation for
non-ST elevation infarction is not associated with
Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Kereiakes
Figure 4
Average total hospital cost (mean ± SD) for treating a patient with
unstable angina for each treatment cohort. Total cost includes the cost
of abciximab and coronary stents. *P £ 0.00005. Adapted with
permission from [39].
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Figure 5
Proposed algorithm for assessment and treatment of patients with
unstable angina or non-ST segment elevation myocardial infarction
(MI). Patients judged to be at high risk on the basis of symptom
complex, electrocardiographic ST segment depression or elevation in
serum troponin level are eligible for adjunctive platelet GP IIb/IIIa
inhibitor therapy and early coronary angiography. ER, emergency room;
Tele, telemetry; CCU, coronary care unit. Adapted with permission
from [39].
Unstable angina/non-ST MI
High risk
Stress test
No ischemia
• Medical anti-ischemic therapy
• Noncardiac work-up
• Risk factor modification
“Upstream” GP IIb/IIIa
in ER/Tele/CCU
Catheterization laboratory
“traditional” GP IIb/IIIa
Revascularization
as feasible/indicated
Not high risk
Provocable
ischemiaincreased risk for mortality. Patients determined to be not
at high risk should undergo appropriate diagnostic testing.
Thus, efficient and effective therapy can now be offered to
patients with non-ST elevation ACS. Empirically defined
periods of medical stabilization most likely add cost
without incremental benefit.
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